ATE370228T1 - Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen - Google Patents

Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen

Info

Publication number
ATE370228T1
ATE370228T1 AT03744903T AT03744903T ATE370228T1 AT E370228 T1 ATE370228 T1 AT E370228T1 AT 03744903 T AT03744903 T AT 03744903T AT 03744903 T AT03744903 T AT 03744903T AT E370228 T1 ATE370228 T1 AT E370228T1
Authority
AT
Austria
Prior art keywords
bacteriophages
bacterium
lysing
infecting
bacteria
Prior art date
Application number
AT03744903T
Other languages
English (en)
Inventor
Mark Rapson
Faith Burden
Liudmilla Glancey
David Hodgson
Nicholas Mann
Original Assignee
Univ Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0207021.7A external-priority patent/GB0207021D0/en
Application filed by Univ Warwick filed Critical Univ Warwick
Application granted granted Critical
Publication of ATE370228T1 publication Critical patent/ATE370228T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03744903T 2002-03-25 2003-03-19 Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen ATE370228T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0207021.7A GB0207021D0 (en) 2002-03-25 2002-03-25 Anti-bacterial agents
US10/215,056 US20030180319A1 (en) 2002-03-23 2002-08-07 Antibacterial agents

Publications (1)

Publication Number Publication Date
ATE370228T1 true ATE370228T1 (de) 2007-09-15

Family

ID=28456031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03744903T ATE370228T1 (de) 2002-03-25 2003-03-19 Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen

Country Status (10)

Country Link
EP (1) EP1504088B1 (de)
JP (1) JP2005520545A (de)
CN (1) CN1643139A (de)
AT (1) ATE370228T1 (de)
AU (1) AU2003226499A1 (de)
CA (1) CA2479897A1 (de)
DE (1) DE60315636T2 (de)
DK (1) DK1504088T3 (de)
ES (1) ES2292996T3 (de)
WO (1) WO2003080823A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1677834B1 (de) * 2003-10-06 2014-01-08 Gangagen, Inc. Therapeutischer phage mit definierter dosis
US20060153811A1 (en) * 2005-01-10 2006-07-13 Jackson Lee E Use of viruses and virus-resistant microorganisms for controlling microorganism populations
JP5127708B2 (ja) * 2005-07-12 2013-01-23 マイクレオス べスローテン フェンノートシャップ バクテリオファージ及びその使用
CA2648232A1 (en) * 2006-04-04 2007-10-11 Centre National De La Recherche Scientifique - Cnrs Process of production of bacteriophage compositions and methods in phage therapy field
CN101835384B (zh) * 2007-10-04 2014-07-16 诺沃莱蒂克斯有限公司 抗菌组合物
GB0800149D0 (en) * 2008-01-04 2008-02-13 Novolytics Ltd Improved host range phage
EP3263588A1 (de) * 2008-07-03 2018-01-03 The Rockefeller University Molécule isolée soluble se liant spécifiquement à staphylococcus
GB2466177A (en) * 2008-12-03 2010-06-16 Arab Science & Technology Found Bacteriophage selection and breeding
JP5701777B2 (ja) * 2009-02-06 2015-04-15 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー 抗菌性ファージ、ファージペプチド、及びそれらの使用方法
WO2011154007A1 (en) * 2010-06-08 2011-12-15 Leah Robert Bacteriophages for use against bacterial infections
SG188566A1 (en) 2010-09-17 2013-04-30 Tecnifar Ind Tecnica Farmaceutica S A Antibacterial phage, phage peptides and methods of use thereof
DK2833899T3 (da) 2012-03-19 2020-09-28 Tecnifar Ind Tecnica Farmaceutica S A Sammensætninger, der omfatter cocktails af antibakterielle fager, og anvendelser deraf til behandling af bakterieinfektioner
EP3656390B1 (de) * 2012-05-04 2023-10-18 Armata Pharmaceuticals, Inc. Therapeutische bakteriophagenzusammensetzungen
GB201402139D0 (en) 2014-02-07 2014-03-26 Fixed Phage Ltd Treatment of topical and systemic bacterial infections
WO2016066722A2 (en) * 2014-10-28 2016-05-06 Ian Humphery-Smith Bacteriophage combinations for human or animal therapy
CN110656093A (zh) * 2019-10-12 2020-01-07 山东省农业科学院畜牧兽医研究所 一种新型沙门氏菌噬菌体库及其应用
CN111826309A (zh) * 2020-06-30 2020-10-27 武汉合缘绿色生物股份有限公司 一种液体生物营养菌剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2251724A1 (en) * 1996-04-15 1997-10-23 Paul Averback Compositions containing bacteriophages and methods of using bacteriophages to treat infections
ATE313341T1 (de) * 2000-01-11 2006-01-15 Intralytix Inc Polymermischungen als bioabbaubare matrizen zur herstellung von biokompositen

Also Published As

Publication number Publication date
CA2479897A1 (en) 2003-10-02
DK1504088T3 (da) 2007-12-17
CN1643139A (zh) 2005-07-20
AU2003226499A1 (en) 2003-10-08
EP1504088B1 (de) 2007-08-15
WO2003080823A3 (en) 2003-12-11
EP1504088A2 (de) 2005-02-09
DE60315636D1 (de) 2007-09-27
JP2005520545A (ja) 2005-07-14
WO2003080823A8 (en) 2004-12-16
DE60315636T2 (de) 2008-05-08
ES2292996T3 (es) 2008-03-16
WO2003080823A2 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
DE60315636D1 (de) Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen
Khosravi et al. The prevalence of genes encoding leukocidins in Staphylococcus aureus strains resistant and sensitive to methicillin isolated from burn patients in Taleghani Hospital, Ahvaz, Iran
Uchiyama et al. DNase Sda1 allows invasive M1T1 Group A Streptococcus to prevent TLR9-dependent recognition
Nunes et al. Antimicrobial susceptibility of Portuguese isolates of Staphylococcus aureus and Staphylococcus epidermidis in subclinical bovine mastitis
Verma et al. Linezolid attenuates lethal lung damage during postinfluenza methicillin-resistant Staphylococcus aureus pneumonia
Månsson et al. Sequence types of Staphylococcus epidermidis associated with prosthetic joint infections are not present in the laminar airflow during prosthetic joint surgery
González-Olvera et al. Antibiotic resistance, virulence factors and genotyping of Pseudomonas aeruginosa in public hospitals of northeastern Mexico
Rehman et al. Prevalence and antibiotic susceptibility of clinical staphylococcus aureus isolates in various specimens collected from a tertiary care hospital, Hayatabad, Peshawar, Pakistan.: Antibiotic susceptibility of clinical staphylococcus aureus isolates in various specimens
Klotz et al. Possible risk for re-colonization with methicillin-resistant Staphylococcus aureus (MRSA) by faecal transmission
Adeoye-Isijola et al. Vancomycin intermediate resistant Staphylococcus aureus in the nasal cavity of asymptomatic individuals: a potential public health challenge
Pardo et al. Characteristics of Community‐Associated Methicillin‐Resistant Staphylococcus aureus (CA‐MRSA) Strains Isolated from Skin and Soft‐Tissue Infections in Uruguay
Moghaddam et al. Isolation and genetic characterization of vancomycin-resistant and mecC+ methicillin-resistant Staphylococcus aureus strains in clinical samples of Bojnurd, Northeastern Iran
Dai et al. Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori
Mtsher et al. Estimation of erythromycin and inducible clindamycin resistance in Saphylococcus aureus isolated from clinical cases
Meenatchi et al. A narrative overview of Staphylococcus haemolyticus: resistance traits, virulence factors, and health impact
Kumar et al. Prevalence of MRSA and antimicrobial susceptibility Staphylococcus aureus in clinical samples in national capital region, India
Achmit et al. Antimicrobial resistance and detection of biofilm in Staphylococcus aureus isolates from Casablanca
Apriliana et al. Resistance finding of Bacillus anthracis towards penicillin in east java, central java, and yogyakarta provinces, Indonesia
Wankhade et al. Study of antibiotic resistance profiling of Staphylococcus aureus isolated from clinical specimens of the patients attending a tertiary teaching hospital from Chhattisgarh
Gupta et al. Occurrence of inducible clindamycin resistance in clinical isolates of Staphylococcus aureus in a tertiary care hospital
Obajuluwa et al. Antibiotics susceptibility pattern of coagulase negative staphylococci isolates from orthopaedic patients
Siddig et al. Prevalence and antimicrobial profile of colonized Enterococcus species isolated from hospitalized and non-hospitalized patients
Fadhil et al. Study of the Effect of some Antibiotics on Pseudomonas Aeruginosa Isolated from Wound and Burn Abscesses
Cuny et al. Outbreak of nosocomial infections with two different MRSA-strains involved: significance of genomic DNA fragment patterns in strains otherwise difficult to type
Sen et al. Antimicrobial susceptibility profile of Staphylococcus aureus isolated from pyogenic infections-Variations encountered at secondary and tertiary care level centres

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties